Impact of passing through rebates at the POS for diabetes medicines
Diabetes imposes a significant economic burden on Medicare, at a cost of more than $100 billion annually. Adherence to prescription medicines to treat diabetes is associated with better disease management and lower overall health care spending, yet high beneficiary out-of-pocket (OOP) costs are a common barrier to proper adherence. Passing through a share of negotiated manufacturer rebates to patients at the point of sale (POS) is a recently debated approach to lower patient OOP costs, but little attention has been paid to its potential to improve adherence and generate downstream savings.
To fill this critical data gap, we modeled the effects of passing through rebates at POS on Medicare Parts A and B spending as a result of improved adherence. This is the first research to quantify these effects. We estimate that for each beneficiary using brand diabetes medicines in the Part D coverage gap or catastrophic phase, passing through a portion of rebates at the POS would reduce overall per beneficiary healthcare spending by $1,352 and lower patient OOP spending by $367 in one year. Over the next 10 years, we project that passing through rebates at the POS for diabetes medicines could reduce total medical spending by approximately $20 billion. These findings highlight the capability of passing through rebates to not only improve access to recommended medicines, but also to improve health outcomes and reduce overall healthcare spending.
These results suggest that the adherence improvements resulting from passing through a portion of rebates could generate substantial savings across the entire Medicare program.
Additional details are available in the complete report. This research is supported by funding from Pharmaceutical Research and Manufacturers of America (PhRMA).
- United States experience dramatic shift in public share of healthcare spending
- Population health outcomes of American patients under different drug access conditions
- Improving Access to Medication-Assisted Treatment for Opioid Use Disorder among the Commercially-insured US Population
- Humira faces up to intense biosimilar competition
- 2018 ISPOR Europe research on IRP
- Our pricing and reimbursement research presented at ISPOR Europe
- ISPOR Europe 2018 Barcelona
- Rapid changes in the global IRP environment
International reference pricing of pharmaceuticals: Apply liberally or use sparingly? See our research from… https://t.co/d7R2S7KZVJ
We are at ISPOR Europe 2018 in Barcelona, Spain! Come see our posters tomorrow at 8:30 PHP359 and PHP48